vs
Electromed, Inc.（ELMD）与LivaNova PLC（LIVN）财务数据对比。点击上方公司名可切换其他公司
LivaNova PLC的季度营收约是Electromed, Inc.的19.1倍（$360.9M vs $18.9M）。Electromed, Inc.净利率更高（14.6% vs 8.6%，领先6.0%）。Electromed, Inc.同比增速更快（16.3% vs 12.1%）。LivaNova PLC自由现金流更多（$50.2M vs $2.4M）。过去两年Electromed, Inc.的营收复合增速更高（16.7% vs 10.6%）
Electromed, Inc.是一家专注于呼吸护理设备研发、生产与销售的医疗设备企业，核心产品为高频胸壁振荡排痰系统，主要服务美国市场的家庭护理及临床医疗机构，为囊性纤维化、慢阻肺等呼吸系统疾病患者提供气道清理解决方案。
LivaNova PLC是一家深耕医疗设备领域的企业，总部位于英国，核心业务为研发心脏外科及神经调控类医疗设备。该公司由美国Cyberonics公司与意大利Sorin公司于2015年以27亿美元对价合并成立，目前在纳斯达克挂牌交易，股票代码为LIVN。
ELMD vs LIVN — 直观对比
营收规模更大
LIVN
是对方的19.1倍
$18.9M
营收增速更快
ELMD
高出4.1%
12.1%
净利率更高
ELMD
高出6.0%
8.6%
自由现金流更多
LIVN
多$47.8M
$2.4M
两年增速更快
ELMD
近两年复合增速
10.6%
损益表 — Q2 2026 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $18.9M | $360.9M |
| 净利润 | $2.8M | $30.9M |
| 毛利率 | 78.4% | 65.2% |
| 营业利润率 | 19.2% | 11.8% |
| 净利率 | 14.6% | 8.6% |
| 营收同比 | 16.3% | 12.1% |
| 净利润同比 | 40.3% | -44.7% |
| 每股收益（稀释后） | $0.32 | $0.57 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELMDLIVN
| Q4 25 | $18.9M | $360.9M | ||
| Q3 25 | $16.9M | $357.8M | ||
| Q2 25 | $17.4M | $352.5M | ||
| Q1 25 | $15.7M | $316.9M | ||
| Q4 24 | $16.3M | $321.8M | ||
| Q3 24 | $14.7M | $318.1M | ||
| Q2 24 | $14.8M | $318.6M | ||
| Q1 24 | $13.9M | $294.9M |
净利润ELMDLIVN
| Q4 25 | $2.8M | $30.9M | ||
| Q3 25 | $2.1M | $26.8M | ||
| Q2 25 | $2.2M | $27.2M | ||
| Q1 25 | $1.9M | $-327.3M | ||
| Q4 24 | $2.0M | $55.9M | ||
| Q3 24 | $1.5M | $33.0M | ||
| Q2 24 | $1.8M | $16.3M | ||
| Q1 24 | $1.5M | $-41.9M |
毛利率ELMDLIVN
| Q4 25 | 78.4% | 65.2% | ||
| Q3 25 | 78.1% | 68.4% | ||
| Q2 25 | 78.3% | 67.8% | ||
| Q1 25 | 78.0% | 69.7% | ||
| Q4 24 | 77.7% | 68.2% | ||
| Q3 24 | 78.3% | 70.8% | ||
| Q2 24 | 76.2% | 68.7% | ||
| Q1 24 | 74.8% | 70.3% |
营业利润率ELMDLIVN
| Q4 25 | 19.2% | 11.8% | ||
| Q3 25 | 15.8% | 15.1% | ||
| Q2 25 | 17.5% | 15.4% | ||
| Q1 25 | 13.6% | 15.3% | ||
| Q4 24 | 15.6% | 11.5% | ||
| Q3 24 | 13.2% | 11.2% | ||
| Q2 24 | 15.7% | 12.6% | ||
| Q1 24 | 13.3% | 5.5% |
净利率ELMDLIVN
| Q4 25 | 14.6% | 8.6% | ||
| Q3 25 | 12.6% | 7.5% | ||
| Q2 25 | 12.7% | 7.7% | ||
| Q1 25 | 12.1% | -103.3% | ||
| Q4 24 | 12.1% | 17.4% | ||
| Q3 24 | 10.0% | 10.4% | ||
| Q2 24 | 12.3% | 5.1% | ||
| Q1 24 | 10.8% | -14.2% |
每股收益（稀释后）ELMDLIVN
| Q4 25 | $0.32 | $0.57 | ||
| Q3 25 | $0.25 | $0.49 | ||
| Q2 25 | $0.26 | $0.50 | ||
| Q1 25 | $0.21 | $-6.01 | ||
| Q4 24 | $0.22 | $1.04 | ||
| Q3 24 | $0.16 | $0.60 | ||
| Q2 24 | $0.20 | $0.30 | ||
| Q1 24 | $0.17 | $-0.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $13.8M | $635.6M |
| 总债务越低越好 | — | $376.1M |
| 股东权益账面价值 | $45.4M | $1.2B |
| 总资产 | $54.9M | $2.6B |
| 负债/权益比越低杠杆越低 | — | 0.31× |
8季度趋势，按日历期对齐
现金及短期投资ELMDLIVN
| Q4 25 | $13.8M | $635.6M | ||
| Q3 25 | $14.1M | $646.1M | ||
| Q2 25 | $15.3M | $593.6M | ||
| Q1 25 | $15.2M | $738.4M | ||
| Q4 24 | $16.2M | $428.9M | ||
| Q3 24 | $13.9M | $346.4M | ||
| Q2 24 | $16.1M | $329.2M | ||
| Q1 24 | $11.7M | $309.2M |
总债务ELMDLIVN
| Q4 25 | — | $376.1M | ||
| Q3 25 | — | $434.5M | ||
| Q2 25 | — | $430.6M | ||
| Q1 25 | — | $628.2M | ||
| Q4 24 | — | $627.0M | ||
| Q3 24 | — | $625.5M | ||
| Q2 24 | — | $624.5M | ||
| Q1 24 | — | $623.8M |
股东权益ELMDLIVN
| Q4 25 | $45.4M | $1.2B | ||
| Q3 25 | $44.7M | $1.2B | ||
| Q2 25 | $43.2M | $1.1B | ||
| Q1 25 | $43.9M | $1.0B | ||
| Q4 24 | $43.6M | $1.3B | ||
| Q3 24 | $41.5M | $1.3B | ||
| Q2 24 | $44.5M | $1.2B | ||
| Q1 24 | $42.5M | $1.2B |
总资产ELMDLIVN
| Q4 25 | $54.9M | $2.6B | ||
| Q3 25 | $53.6M | $2.6B | ||
| Q2 25 | $53.8M | $2.5B | ||
| Q1 25 | $52.5M | $2.6B | ||
| Q4 24 | $52.3M | $2.5B | ||
| Q3 24 | $48.9M | $2.5B | ||
| Q2 24 | $52.2M | $2.5B | ||
| Q1 24 | $48.9M | $2.5B |
负债/权益比ELMDLIVN
| Q4 25 | — | 0.31× | ||
| Q3 25 | — | 0.38× | ||
| Q2 25 | — | 0.38× | ||
| Q1 25 | — | 0.61× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.48× | ||
| Q2 24 | — | 0.50× | ||
| Q1 24 | — | 0.51× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.0M | $82.4M |
| 自由现金流经营现金流 - 资本支出 | $2.4M | $50.2M |
| 自由现金流率自由现金流/营收 | 12.7% | 13.9% |
| 资本支出强度资本支出/营收 | 3.4% | 8.9% |
| 现金转化率经营现金流/净利润 | 1.10× | 2.67× |
| 过去12个月自由现金流最近4个季度 | $7.9M | $173.3M |
8季度趋势，按日历期对齐
经营现金流ELMDLIVN
| Q4 25 | $3.0M | $82.4M | ||
| Q3 25 | $169.0K | $85.1M | ||
| Q2 25 | $3.9M | $62.9M | ||
| Q1 25 | $2.1M | $24.0M | ||
| Q4 24 | $3.2M | $78.7M | ||
| Q3 24 | $2.3M | $51.0M | ||
| Q2 24 | $4.5M | $43.4M | ||
| Q1 24 | $1.4M | $10.0M |
自由现金流ELMDLIVN
| Q4 25 | $2.4M | $50.2M | ||
| Q3 25 | $-83.0K | $62.2M | ||
| Q2 25 | $3.7M | $47.8M | ||
| Q1 25 | $1.9M | $13.2M | ||
| Q4 24 | $2.9M | $68.3M | ||
| Q3 24 | $2.3M | $32.8M | ||
| Q2 24 | $4.5M | $31.2M | ||
| Q1 24 | $1.3M | $3.6M |
自由现金流率ELMDLIVN
| Q4 25 | 12.7% | 13.9% | ||
| Q3 25 | -0.5% | 17.4% | ||
| Q2 25 | 21.4% | 13.6% | ||
| Q1 25 | 12.2% | 4.2% | ||
| Q4 24 | 18.0% | 21.2% | ||
| Q3 24 | 15.5% | 10.3% | ||
| Q2 24 | 30.1% | 9.8% | ||
| Q1 24 | 9.1% | 1.2% |
资本支出强度ELMDLIVN
| Q4 25 | 3.4% | 8.9% | ||
| Q3 25 | 1.5% | 6.4% | ||
| Q2 25 | 0.8% | 4.3% | ||
| Q1 25 | 1.0% | 3.4% | ||
| Q4 24 | 1.4% | 3.2% | ||
| Q3 24 | 0.3% | 5.7% | ||
| Q2 24 | 0.1% | 3.8% | ||
| Q1 24 | 0.6% | 2.2% |
现金转化率ELMDLIVN
| Q4 25 | 1.10× | 2.67× | ||
| Q3 25 | 0.08× | 3.18× | ||
| Q2 25 | 1.75× | 2.32× | ||
| Q1 25 | 1.10× | — | ||
| Q4 24 | 1.60× | 1.41× | ||
| Q3 24 | 1.57× | 1.55× | ||
| Q2 24 | 2.46× | 2.65× | ||
| Q1 24 | 0.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELMD
暂无分部数据
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
